Why Provention Bio Shares Are Skyrocketing Today
Provention Bio Inc (NASDAQ: PRVB) shares are trading higher by 20.6% to $5.97 Thursday morning after the company announced it has entered into a co-promotion agreement with Sanofi U.S. for the launch of its lead investigational drug candidate teplizumab.
What Else?
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate
Provention Bio Inc (NASDAQ:PRVB) has entered into a co-promotion agreement with Sanofi SA (NASDAQ:SNY) to launch Provention’s lead investigational candidate, teplizumab, to delay…
Jefferies Initiates Coverage On Provention Bio with Buy Rating, Announces Price Target of $10
Jefferies analyst Chris Howerton initiates coverage on Provention Bio (NASDAQ:PRVB) with a Buy rating and announces Price Target of $10.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: